Hematologists and oncologists from UC San Francisco shared research results and clinical guidance at the world’s premier meeting for malignant and non-malignant hematology at the American Society of ...
Teclistamab (Tecvayli) is an off-the-shelf first-in-class bispecific monoclonal antibody shown in the MajesTEC-1 trial to ...
LINKER-MM4 trial shows linvoseltamab monotherapy achieves a 79% overall response rate in newly diagnosed MM patients, with 92 ...
The latest data released at ASH 2025 offer new combination therapies for the treatment of multiple myeloma and new insights into the disease.
Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced positive topline results from the Phase ...
Johnson & Johnson’s Tecvayli (teclistamab-cqyv), used in combination with daratumumab to treat relapsed or refractory multiple myeloma, has received FDA’s latest national priority voucher, becoming ...
Under a program designed to accelerate the approval of products that could address key national priorities, the FDA awarded a ...
The FDA has awarded its latest national priority voucher to Johnson & Johnson’s Tecvayli (teclistamab-cqyv) in combination with daratumumab for the treatment of relapsed or refractory multiple myeloma ...
An in vivo chimeric antigen receptor T-cell therapy administered without lymphodepletion exhibited activity among patients with advanced multiple myeloma, according to findings presented at ASH Annual ...
Supportive care, including intravenous immunoglobulin, may improve outcomes by reducing infection risk in patients treated ...
Dr Rahul Banerjee discusses ASH 2025 and bispecific antibodies in myeloma, including data from MajesTEC-3, IFM2021-01, and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback